Literature DB >> 18852632

Altered eicosanoid metabolism in the cystic fibrosis mouse small intestine.

Robert C De Lisle1, Lauren Meldi, Maureen Flynn, Kyle Jansson.   

Abstract

OBJECTIVES: Imbalances in essential fatty acid levels have been reported in cystic fibrosis (CF), which may relate to elevated proinflammatory eicosanoid generation. The aim of this work was to better define eicosanoid metabolism in the CF intestine.
MATERIALS AND METHODS: We used the small intestine of the cystic fibrosis transmembrane conductance regulator knockout mouse (CF mouse) to measure eicosanoid metabolic gene expression by quantitative reverse transcription polymerase chain reaction and Western blot, and eicosanoid levels by enzyme immunoassay, as compared with wild-type (WT) littermates.
RESULTS: In the CF small intestine, expression of the secretory phospholipase A2 Pla2g5 mRNA was upregulated to 980% of WT levels. The following were downregulated: leukotriene C4 synthase Ltc4s (mRNA 55% of WT); omega-hydroxylase cytochrome P450s Cyp2c40 (mRNA 54% of WT), and Cyp4a10 (mRNA 4% of WT); and the major prostaglandin degradative enzymes prostaglandin dehydrogenase Hpgd (mRNA 27% of WT) and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase Ltb4dh (mRNA 64% and protein 30% of WT). The prostaglandins PGE2 and PGF2alpha were increased to 400% to 600% of WT levels in the CF mouse intestine, and the hydroxyeicosatetraenoic acids (HETEs) 12-, 15-, and 20-HETE were decreased to 3% to 20% of WT levels.
CONCLUSIONS: There are changes in eicosanoid metabolic gene expression that are accompanied by significant changes in specific eicosanoid levels. These changes are expected to play important roles in the pathophysiology of CF in the intestine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852632     DOI: 10.1097/MPG.0b013e31817e0f2c

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  10 in total

1.  D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice.

Authors:  Mohamad Navab; Srinivasa T Reddy; G M Anantharamaiah; Greg Hough; Georgette M Buga; Jan Danciger; Alan M Fogelman
Journal:  J Lipid Res       Date:  2011-12-13       Impact factor: 5.922

2.  Cystic fibrosis transmembrane conductance regulator modulates enteric cholinergic activities and is abnormally expressed in the enteric ganglia of patients with slow transit constipation.

Authors:  Ka Ming Yeh; Olle Johansson; Huy Le; Karan Rao; Irit Markus; Dayashan Shevy Perera; David Zachary Lubowski; Denis Warwick King; Li Zhang; Hongzhuan Chen; Lu Liu
Journal:  J Gastroenterol       Date:  2019-08-07       Impact factor: 7.527

3.  DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity.

Authors:  Sarah W Njoroge; Michael Laposata; Waddah Katrangi; Adam C Seegmiller
Journal:  J Lipid Res       Date:  2011-11-16       Impact factor: 5.922

4.  Intestinal smooth muscle dysfunction develops postnatally in cystic fibrosis mice.

Authors:  Robert C De Lisle; Lauren Meldi; Racquel Mueller
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-12       Impact factor: 2.839

Review 5.  Role for animal models in understanding essential fatty acid deficiency in cystic fibrosis.

Authors:  Deanne H Hryciw; Courtney A Jackson; Nirajan Shrestha; David Parsons; Martin Donnelley; Andrew J McAinch
Journal:  Cell Mol Life Sci       Date:  2021-11-05       Impact factor: 9.261

6.  Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.

Authors:  Robert C De Lisle; Racquel Mueller; Eileen Roach
Journal:  BMC Gastroenterol       Date:  2010-09-15       Impact factor: 3.067

7.  Enteric circular muscle dysfunction in the cystic fibrosis mouse small intestine.

Authors:  R C de Lisle; R Sewell; L Meldi
Journal:  Neurogastroenterol Motil       Date:  2009-10-08       Impact factor: 3.598

Review 8.  The cystic fibrosis intestine.

Authors:  Robert C De Lisle; Drucy Borowitz
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

Review 9.  Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions.

Authors:  Rachel Y Tam; Josie M van Dorst; Isabelle McKay; Michael Coffey; Chee Y Ooi
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

Review 10.  Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications.

Authors:  Adam C Seegmiller
Journal:  Int J Mol Sci       Date:  2014-09-11       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.